Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Autor: Feng, S, Phillips, DJ, White, T, Sayal, H, Aley, PK, Bibi, S, Dold, C, Fuskova, M, Gilbert, SC, Hirsch, I, Humphries, HE, Jepson, B, Kelly, EJ, Plested, E, Shoemaker, K, Thomas, KM, Vekemans, J, Villafana, TL, Lambe, T, Pollard, AJ, Voysey, M, Adlou, S, Allen, L, Angus, B, Anslow, R, Asselin, M-C, Baker, N, Baker, P, Barlow, T, Beveridge, A, Bewley, KR, Brown, P, Brunt, E, Buttigieg, KR, Camara, S, Charlton, S, Chiplin, E, Cicconi, P, Clutterbuck, EA, Collins, AM, Coombes, NS, Clemens, SAC, Davison, M, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Emary, KRW, Ewer, KJ, Felle, S, Ferreira, DM, Finn, A, Folegatti, PM, Fothergill, R, Fraser, S, Garlant, H, Gatcombe, L, Godwin, KJ, Goodman, AL, Green, CA, Hallis, B, Hart, TC, Heath, PT, Hill, H, Hill, AVS, Jenkin, D, Kasanyinga, M, Kerridge, S, Knight, C, Leung, S, Libri, V, Lillie, PJ, Marinou, S, McGlashan, J, McGregor, AC, McInroy, L, Minassian, AM, Mujadidi, YF, Penn, EJ, Petropoulos, CJ, Pollock, KM, Proud, PC, Provstgaard-Morys, S, Rajapaska, D, Ramasamy, MN, Sanders, K, Shaik, I, Singh, N, Smith, A, Snape, MD, Song, R, Shrestha, S, Sutherland, RK, Thomson, EC, Turner, DPJ, Webb-Bridges, A, Wrin, T, Williams, CJ
Přispěvatelé: Group, Oxford COVID Vaccine Trial
Rok vydání: 2021
Předmět:
Male
Antibodies
Viral
Neutralization
Cohort Studies
Multiplex
Asymptomatic Infections
11 Medical and Health Sciences
Aged
80 and over
Vaccines
biology
medicine.diagnostic_test
Vaccination
General Medicine
Middle Aged
Titer
Treatment Outcome
Infectious diseases
Female
Antibody
medicine.symptom
Adult
medicine.medical_specialty
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19)
Adolescent
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Immunology
Immunization
Secondary
Asymptomatic
General Biochemistry
Genetics and Molecular Biology
World health
Article
Young Adult
Immune system
Statistical significance
Internal medicine
medicine
Humans
Aged
Infection Control
business.industry
SARS-CoV-2
Patient Acuity
COVID-19
Vaccine efficacy
Antibodies
Neutralizing
United Kingdom
Immunity
Humoral
Immunoassay
biology.protein
business
Zdroj: Nature Medicine
ISSN: 1546-170X
Popis: The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.
Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine ChAdOx1 nCoV-19 are identified as correlates of protection against symptomatic infection.
Databáze: OpenAIRE
Externí odkaz: